|
|
Nexavant |
|
Vaxjo ID |
182 |
|
Vaccine Adjuvant Name |
Nexavant |
|
Adjuvant VO ID |
VO_0006108
|
|
Description |
nucleic acid vaccine adjuvant that targets on TLR3 agonist to induce a mixed Th1/Th2 response |
|
Stage of Development |
Research |
|
Location Licensed |
South Korea (NA Vaccine Institute) |
|
Host Species for Testing |
3 |
|
Second Host Species for Testing |
19 |
|
Components |
partial nucleotide segment |
|
Storage |
room temp |
|
Preparation |
partial nucleotide segment (1,701-2,112; 412 nucleotides) was selectively cloned, and ssRNAs were digested by treatment with RNase T1 instead of RNase A |
|
Function |
innate immune activation, Induces CD8 T cells |
| References |
(Cha, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=94]
Ko et al., 2023: Ko KH, Cha SB, Lee SH, Bae HS, Ham CS, Lee MG, Kim DH, Han SH. A novel defined TLR3 agonist as an effective vaccine adjuvant. Frontiers in immunology. 2023; 14; 1075291. [PubMed: 36761735].
|
|
